Health ❯ Healthcare ❯ Cancer

Immunotherapy

Pembrolizumab mRNA Vaccines Keytruda Checkpoint Inhibitors Personalized Medicine Immune Checkpoint Inhibitors CAR-T Therapy Regulatory T Cells Drug Development Vaccimel Oncolytic Virus Therapy Natural Killer Cells Immune Response Therapeutic Vaccines Biomarkers Patient Care TIM-3 Amphiregulin Targeted Therapy Chimeric Antigen Receptor (CAR) Neoantigen Therapy Research Side Effects Pediatric Cancer Treatment T-cell Therapy Patient Experiences Cancer Vaccines CAR-T Cell Therapy Durvalumab Atezolizumab Clinical Trials

Personalized mRNA Vaccine Halves Five‑Year Melanoma Recurrence Risk

Five‑year results show durable drops in metastasis with higher survival, leaving phase 3 confirmation plus manufacturing scale‑up as remaining needs.

Personalized mRNA Vaccine Shows Durable Survival Signal in Early Pancreatic Cancer

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

Ligand-Based OSM CAR-T Shows Preclinical Efficacy Against Osteosarcoma

mRNA COVID Vaccines Linked to Longer Survival With Checkpoint Immunotherapy, Peer‑Reviewed Study Finds

mRNA COVID Vaccination Linked to Longer Survival With Cancer Immunotherapy, Data Presented at ESMO

Adjuvant Pembrolizumab Cuts Risk of Distant Metastases in Merkel Cell Carcinoma at ESMO 2025

NICE Approves Keytruda Combo for Advanced Endometrial Cancer on NHS

Meta-Analysis Shows 43% Overall Response for Fecal Transplants Combined with Cancer Immunotherapy

Phase 3 Trial Launches to Test Electric Field and Immunotherapy Combo in Glioblastoma

Atezolizumab-Enhanced Chemotherapy Halves Recurrence in Stage III dMMR Colon Cancer

Study Finds NAD Decline Drives Age-Related CAR-T Cell Therapy Failures